Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 57.8%

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Approximately 1.3% of the company's stock are short sold. Based on an average daily trading volume, of 66,900 shares, the short-interest ratio is presently 0.8 days.

Monopar Therapeutics Price Performance

MNPR traded up $4.73 during trading on Wednesday, reaching $39.10. 46,159 shares of the company's stock were exchanged, compared to its average volume of 359,032. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.30. The company's fifty day simple moving average is $36.16 and its 200-day simple moving average is $21.99. The stock has a market capitalization of $238.59 million, a P/E ratio of -19.85 and a beta of 1.18.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MNPR. Janus Henderson Group PLC acquired a new stake in Monopar Therapeutics during the 4th quarter worth about $23,435,000. Adage Capital Partners GP L.L.C. purchased a new position in Monopar Therapeutics during the fourth quarter valued at approximately $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. Point72 Asset Management L.P. purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Monopar Therapeutics during the 4th quarter worth approximately $2,861,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms recently commented on MNPR. Piper Sandler reissued an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday. HC Wainwright increased their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, January 22nd.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.